News
>All
FDA Approves Venetoclax Plus LDAC For Older Patients With Newly Diagnosed AML
October 16th 2020The FDA granted approval to venetoclax in combination with azacitidine, decitabine, or low-dose cytarabine, a regimen known as LDAC, as treatment of adults patients with aged 75 years or older with newly-diagnosed acute myeloid leukemia or who have comorbidities precluding intensive induction chemotherapy.
Safety of Guadecitabine Consistent Across Phase 3 Trials in Various Hematologic Malignancies
October 16th 2020Two phase 3 clinical trials demonstrated consistent safety findings with the expected safety profile of guadecitabine as treatment of 2 patient populations, including patients with previously treated acute myeloid leukemia in ASTRAL-2 and patients with previously treated myelodysplastic syndrome or chronic myelomonocytic leukemia in ASTRAL-3.
Real-World Data Support Use of Polatuzumab Vedotin for Heavily Pretreated Patients with R/R DLBCL
October 16th 2020Patients with relapsed or refractory diffuse large B-cell lymphoma who have not found success in 2 or more lines of therapy face stiff odds, but new data suggest polatuzumab vedotin–based therapies may help improve outcomes.
FDA Grants Orphan Drug Designation to Novel Monoclonal Antibody in Multiple GI Malignancies
October 15th 2020An Orphan Drug Designation had been granted by the FDA to the CD40 antagonistic monoclonal antibody, APX005M for the treatment esophageal and gastroesophageal junction cancer, as well as for the treatment of patients with pancreatic cancer.
The Addition of Sipuleucel-T to Immunotherapy Prolonged Survival in Men with mCRPC
October 15th 2020A significant reduction in the risk of death was observed with the addition of sipuleucel-T to either abiraterone acetate or enzalutamide as treatment of patients with metastatic castration-resistant prostate cancer in a real-world analysis.
Copanlisib Combo Prolongs PFS in Phase 3 Study of Indolent Non-Hodgkin Lymphoma
October 15th 2020The primary end point of prolonged progression-free survival in the phase 3 CHRONOS-3 study was met with copanlisib in combination with rituximab as treatment of patients with indolent non-Hodgkin lymphoma.
ESMO Data Show Benefit of Approved Thyroid Cancer Regimens in Select Patients
October 14th 2020Across subsets of patients with thyroid cancer, an interesting collection of research was shared with oncologists during the 2020 European Society of Medical Oncology Virtual Congress, demonstrating improvement in outcomes for patients with thyroid cancers with newer and established approved regimens.
Combination Therapy Continues to Demonstrate Efficacy in Advanced Renal Cell Carcinoma
October 13th 2020In an interview with Targeted Oncology, Rana R. McKay, MD, discussed the findings from the CheckMate-9ER study of nivolumab plus cabozantinib in patients with advanced or metastatic renal cell carcinoma who had not been previously treated.
Expert Insights on Metastatic Breast Cancer Awareness Day: Treating Patients by Subtype
October 13th 2020A number of targeted agents have been approved in the setting of metastatic breast cancer, which has allowed for more personalized treatment approaches and underscores the importance of genomic testing.
Patient-Reported Outcomes Confirm Tolerability of Selpercatinib in RET-Driven Thyroid Cancer
October 12th 2020In an interview with Targeted Oncology, Lori J. Wirth, MD, discussed the findings from an analysis of the patient-reported outcomes observed in the LIBRETTO-001 study of selpercatinib in patients with RET-driven thyroid cancers.
Enfortumab Vedotin Shows Durable Responses in Pivotal Phase 2 Study of Advanced Urothelial Cancer
October 12th 2020Enfortumab vedotin-ejfv induced durable responses as treatment of patients with locally advanced or metastatic urothelial cancer who have previously received immunotherapy but not a prior platinum-containing chemotherapy and are not eligible for cisplatin.
Investigational Agent Achieves All Secondary End Points in Phase 3 Study of Hematologic Malignancies
October 12th 2020Omidubicel as treatment of patients with high-risk hematologic malignancies induced rapid platelet engraftment and a reduction in the number of infections and hospitalizations, meeting all 3 secondary end points of a phase 3 clinical trial.
Leading Research From ESMO 2020 Further the Potential of Targeted Agents in Breast Cancer
October 9th 2020Breast cancer data reported during the 2020 European Society Medical Oncology Virtual Congress revealed major advances in the treatment paradigm. The agents included in these trials challenged that standard-of-care.
Nobel Prize in Chemistry Goes to Developers of Genome Editing System CRISPR
October 9th 2020The creation of the CRISPR-Cas9, a novel gene-editing technology used in oncology and other areas of scientific research was the antecedent for Emmanuelle Charpentier, PhD, and Jennifer A. Doudna, PhD, being awarded the 2020 Nobel Prize in Chemistry.
Palbociclib Combination Misses Primary End Point of PENELOPE-B in HR+, HER2- Early Breast Cancer
October 9th 2020Palbociclib in combination with standard endocrine therapy did not improve invasive disease-free survival in patients with hormone receptor-positive, HER2-negative early breast cancer who have residual invasive disease after completing neoadjuvant chemotherapy, missing the primary end point of the phase 3 PENELOPE-B trial.
Obinutuzumab Plus DHAP Induces MRD Negativity in Transplant-Eligible Mantle Cell Lymphoma
October 8th 2020Obinutuzumab with dexamethasone plus high-dose cytarabine and cisplatin generated good activity for inducing bone marrow minimal residual disease negativity in patients with mantle cell lymphoma who are eligible for transplant.
FDA Recommends Clinical Trials Include Premenopausal Women With Breast Cancer
October 8th 2020The FDA issued a draft guidance that encourages the inclusion of premenopausal women with breast cancer in clinical trials, which will in order tohelp researchers determine the efficacy of a hormonal drug or biological products for this population along with others.
